Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vanda Pharmaceuticals Inc. Director's Dealing 2025

Jun 9, 2025

33390_dirs_2025-06-09_237c84e4-6ac7-4a0c-8ffa-7ed60f9c2e7c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2025-06-05

Reporting Person: DUGAN RICHARD W (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-06-05 Common Stock A 59225 Acquired 177454 Direct

Footnotes

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.